Dr. Henske Speaking: The name of our research project is the LAM Genome Atlas. The goals of this project are to understand all the different changes that might be occurring at the DNA and RNA level in LAM cells so that we can develop better treatments for women who have this deadly disease. With the ARRA funding we hope to understand the mutations in the DNA that are occurring in LAM cells and ultimately our goal is to use information from the DNA to find better treatments for LAM. Dr. Kwiatkowski Speaking: Our goal is to understand as well as possible how LAM develops and the genetic changes that occur in this diseases are surely very important in that process. We have been thinking about this project for at least several months perhaps a year or two, but did not have sufficient funds to undertake a project of this magnitude. So therefore the ARRA funds are indeed absolutely essential for this work to go forward. Dr. Henske Speaking: One of the really exciting and wonderful things about this particular grant, is the inter-disiplinary nature of the research that we're proposing. This involves collaborations between two different divisions here at the Brigham and Women's Hospital and also involves collaborations with investigators who are at the Dana-Farber Cancer Institute and the Broad Institute and all together I think these studies could not be accomplished by any one of us, they really require this team effort that is being supported through the ARRA.
Elizabeth P. Henske, M.D. Director, Center for LAM Research and Clinical Care, Brigham and Women's Hospital, Boston, Massachusetts The Lymphangioleiomyomatosis (LAM) Genome Atlas Administered by the NHLBI Divisions of Lung Diseases, Lung Biology and Disease Branch FY 2009 Recovery Act Funding: $499,988